Περίληψη:
The prevalence of type 2 diabetes mellitus is rising rapidly in all
developed countries, particularly in the growing population of persons
>50 years of age. As a dangerous consequence, this is accompanied by a
proportionate increase in the incidence of chronic renal disease.
Evidence-based medicine has shown that tight blood glucose control can
delay the onset and retard the progression of diabetic complications,
and while it is a challenge to closely manage the complexity of
diabetes, it is more difficult to effectively treat the multiple
associated comorbidities that develop. Best practice guidelines support
early intervention and aggressive treatment of hypertension,
hyperglycaemia, proteinuria, hypercholesterolemia, and anaemia. To date,
guideline-based management has been proven to be difficult. This article
describes the concept of the IRIDIEM studies. The objective of these
studies is to endorse and facilitate the use of current best practice
guidelines for the management of frequent comorbid diseases and
established risk factors in the treatment of type 2 diabetes associated
with chronic kidney disease. Additionally, IRIDIEM will assess the
impact of this improved disease management model on the progression of
chronic kidney disease that can result from electronically prompting
clinicians with evidence-based treatment advice. Copyright (C) 2004 S.
Karger AG, Basel.
Συγγραφείς:
Lameire, N
Stevens, P
Raptis, S
Thomas, S
Schernthaner,
G
